Fintel reports that on February 11, 2026, Guggenheim initiated coverage of Entrada Therapeutics (NasdaqGM:TRDA) with a Buy recommendation.
Analyst Price Forecast Suggests 69.69% Upside
As of February 4, 2026, the average one-year price target for Entrada Therapeutics is $18.36/share. The forecasts range from a low of $13.13 to a high of $22.05. The average price target represents an increase of 69.69% from its latest reported closing price of $10.82 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Entrada Therapeutics is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -2.88.
What is the Fund Sentiment?
There are 231 funds or institutions reporting positions in Entrada Therapeutics. This is an decrease of 41 owner(s) or 15.07% in the last quarter. Average portfolio weight of all funds dedicated to TRDA is 0.32%, an increase of 8.32%. Total shares owned by institutions decreased in the last three months by 4.43% to 30,447K shares. 
The put/call ratio of TRDA is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 4,866K shares representing 13.57% ownership of the company. No change in the last quarter.
Mpm Asset Management holds 4,381K shares representing 12.22% ownership of the company. No change in the last quarter.
5AM Venture Management holds 4,256K shares representing 11.87% ownership of the company. In its prior filing, the firm reported owning 4,308K shares , representing a decrease of 1.22%. The firm decreased its portfolio allocation in TRDA by 18.77% over the last quarter.
PRNHX - T. Rowe Price New Horizons Fund holds 1,522K shares representing 4.25% ownership of the company. In its prior filing, the firm reported owning 1,686K shares , representing a decrease of 10.71%. The firm decreased its portfolio allocation in TRDA by 27.95% over the last quarter.
Wellington Management Group Llp holds 954K shares representing 2.66% ownership of the company. In its prior filing, the firm reported owning 1,061K shares , representing a decrease of 11.14%. The firm decreased its portfolio allocation in TRDA by 89.40% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
